M42 And Yamagata University Join Forces To Enhance Heavy Ion Therapy Research For Cancer Treatment

M42, a global leader in health technology, has entered into a Memorandum of Cooperation with Yamagata University in Japan. This agreement aims to advance research and innovation in heavy ion therapy, a precise form of radiation therapy for cancer treatment. The collaboration was formalised during M42's recent visit to Japan, highlighting their dedication to pioneering advanced cancer care through innovative medical solutions.

The partnership between M42 and Yamagata University is set to enhance the development of heavy ion therapy. This advanced treatment targets cancerous tumours with precision, minimising damage to surrounding healthy tissues. It addresses a significant gap in advanced cancer treatment options within the UAE and beyond.

M42 and Cleveland Clinic Abu Dhabi have also partnered with Toshiba Energy Systems & Solutions Corporation. Together, they plan to establish the first heavy ion therapy facility in the Middle East, located on the Cleveland Clinic Abu Dhabi campus. This initiative will position Abu Dhabi as a global hub for oncology innovation.

The new facility will be strategically placed near the Fatima bint Mubarak Center, the region’s first comprehensive cancer centre. With no similar centre within a five-hour flight of the UAE, this development will significantly improve access to life-saving treatments for patients across the Middle East.

Japan has been at the forefront of heavy ion therapy research since 1984, achieving its first clinical application in 1994. Today, Japan hosts seven out of 15 global institutes offering this therapy, accounting for 80% of worldwide treatments. Yamagata University's East Japan Heavy Ion Centre is the latest addition to these elite institutions.

Satoru Nagase, Dean of Yamagata University's Faculty of Medicine, expressed enthusiasm about the partnership. "At Yamagata University, we are dedicated to pushing the boundaries of medical research and technological innovation in heavy ion therapy," he stated. The university's expertise includes medical physics and radiological technology among other areas.

Strengthening Global Research Efforts

The collaboration between M42 and Yamagata University aims to strengthen global research efforts and pave the way for advancements in cancer research and treatment. By sharing knowledge and advancing research together, both institutions aim to improve access to effective cancer treatments globally.

Dr. Georges-Pascal Haber from Cleveland Clinic Abu Dhabi highlighted the significance of this partnership: "This partnership represents a pivotal milestone in our ongoing mission to advance oncology care and clinical research." The alliance is expected to drive meaningful innovation in cancer treatment both regionally and globally.

Hasan Jasem Al Nowais, Managing Director and Group CEO of M42, emphasised their commitment: "We are delighted to partner with Yamagata University... By combining our expertise... we are confident that this alliance will drive innovation in cancer care." This collaboration marks a critical step towards advancing oncology care through shared expertise.

This strategic partnership not only enhances knowledge-sharing but also drives scientific breakthroughs that could improve patient outcomes across regions. As M42 plans to open its first heavy ion therapy centre in Abu Dhabi, this collaboration will play a crucial role in shaping future healthcare advancements.

With inputs from WAM